Insulin analogues and cancer risk: cause for concern orcause célèbre?

Hemkens, 2009, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, 52, 1732, 10.1007/s00125-009-1418-4

Jonasson, 2009, Insulin glargine use and short-term cancer incidence-a population-based follow-up in Sweden, Diabetologia, 52, 1745, 10.1007/s00125-009-1444-2

Colhoun, 2009, Use of insulin glargine use and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group, Diabetologia, 52, 1755, 10.1007/s00125-009-1453-1

Currie, 2009, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, 52, 1766, 10.1007/s00125-009-1440-6

Smith, 2009, Editorial: Does diabetes therapy influence the risk of cancer?, Diabetologia, 52, 1699, 10.1007/s00125-009-1441-5

Bowker, 2006, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin, Diabetes Care, 29, 254, 10.2337/diacare.29.02.06.dc05-1558

Kurtzhals, 2000, Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, 49, 999, 10.2337/diabetes.49.6.999

Hansen, 1996, Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency, Biochem J, 315, 271, 10.1042/bj3150271

Heuson, 1967, Cell proliferation induced by insulin in organ culture of rat mammary carcinoma, Exp Cell Res, 45, 351, 10.1016/0014-4827(67)90185-1

Pocock, 2009, Insulin glargine and malignancy: an unwarranted alarm, Lancet, 374, 511, 10.1016/S0140-6736(09)61307-6

Vigneri, 2009, Diabetes and cancer, Endocr Relat Cancer, 16, 1103, 10.1677/ERC-09-0087

Larsson, 2005, Diabetes mellitus and risk of colorectal cancer: a meta-analysis, J Natl Cancer Inst, 97, 1679, 10.1093/jnci/dji375

Larsson, 2007, Diabetes mellitus and risk of breast cancer: a meta-analysis, Int J Cancer, 121, 856, 10.1002/ijc.22717

Huxley, 2005, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies, Br J Cancer, 92, 2076, 10.1038/sj.bjc.6602619

Venkateswaran, 2007, Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts, J Natl Cancer Inst, 99, 1793, 10.1093/jnci/djm231

Stock, 2009, Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts, PLoS Med, 6, e1000201, 10.1371/journal.pmed.1000201

Vander Heiden, 2009, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809

Pollak, 2004, Insulin-like growth factors and neoplasia, Nat Rev Cancer, 4, 505, 10.1038/nrc1387

Pollak, 2008, Insulin and insulin-like growth factor signalling in neoplasia, Nature Rev Cancer, 8, 915, 10.1038/nrc2536

Chokkalingam, 2001, Insulin-like growth factors and prostate cancer: a population-based case-control study in China, Cancer Epidemiol Biomark Prev, 10, 421

Chan, 1998, Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study, Science, 279, 563, 10.1126/science.279.5350.563

Toniolo, 2000, Serum insulin-like growth factor-I and breast cancer, Int J Cancer, 88, 828, 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8

Krajcik, 2002, Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer, Cancer Epidemiol Biomarkers Prev, 11, 1566

Muti, 2002, Fasting glucose is a risk factor for breast cancer: a prospective study, Cancer Epidemiol Biomarkers Prev, 11, 1361

Allen, 2005, A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk, Br J Cancer, 92, 1283, 10.1038/sj.bjc.6602471

Schernhammer, 2006, Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II, Endocr Relat Cancer, 13, 583, 10.1677/erc.1.01149

Kaaks, 2002, Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden, Cancer Causes Control, 13, 307, 10.1023/A:1015270324325

Goodwin, 2002, Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study, J Clin Oncol, 20, 42, 10.1200/JCO.2002.20.1.42

Ma, 2008, Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis, Lancet Oncol, 9, 1039, 10.1016/S1470-2045(08)70235-3

Law, 2008, Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival, Cancer Res, 68, 10238, 10.1158/0008-5472.CAN-08-2755

Cox, 2009, Insulin receptor expression by human prostate cancers, Prostate, 69, 33, 10.1002/pros.20852

de Ostrovich, 2008, Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo, Am J Pathol, 173, 824, 10.2353/ajpath.2008.071005

Novosyadlyy, 2010, Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes, Cancer Res, 70, 741, 10.1158/0008-5472.CAN-09-2141

Osborne, 1976, Hormone responsive human breast cancer in long-term tissue culture: effect of insulin, Proc Natl Acad Sci, 73, 4536, 10.1073/pnas.73.12.4536

Belfiore, 2009, Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease, Endocr Rev, 30, 586, 10.1210/er.2008-0047

Frasca, 2008, The role of insulin receptors and IGF-I receptors in cancer and other diseases, Arch Physiol Biochem, 114, 23, 10.1080/13813450801969715

Sacco, 2009, Differential signalling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A, Endocrinol, 150, 3594, 10.1210/en.2009-0377

Pandini, 2002, Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved, J Biol Chem, 277, 39684, 10.1074/jbc.M202766200

Slieker, 1997, Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor, Diabetologia, 40, S54, 10.1007/s001250051402

Milazzo, 1997, ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor, Mol Carcinog, 18, 19, 10.1002/(SICI)1098-2744(199701)18:1<19::AID-MC3>3.0.CO;2-M

Drejer, 1992, The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake, Diabetes Metab Rev, 8, 259, 10.1002/dmr.5610080305

Shukla, 2009, Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines, Endocrine-Related Cancer, 16, 429, 10.1677/ERC-08-0240

Kohn, 2007, pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity, Peptides, 28, 935, 10.1016/j.peptides.2007.01.012

Stammberger, 2002, Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice, Int J Toxicol, 21, 171, 10.1080/10915810290096306

45Center for Drug Evaluation and Research. Pharmacology Review, insulin glargine (Lantus). US Food and Drug Administration, 2000. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus_pharmr_P1.pdf (accessed 30 October 2009).

Miller, 2007, Commentary: implications of the frequent occurrence of occult carcinoma of the prostate, Int J Epidemiol, 36, 282, 10.1093/ije/dym052

Welch, 1997, Using autopsy series to estimate the disease reservoir for ductal carcinoma in situ of the breast: how much more breast cancer can we find?, Ann Internal Med, 127, 1023, 10.7326/0003-4819-127-11-199712010-00014

Weinstein, 2009, Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells (2009), Diabetes Metab Res Rev, 25, 41, 10.1002/dmrr.912

Evans, 2005, Metformin and reduced risk of cancer in diabetic patients, BMJ, 330, 1304, 10.1136/bmj.38415.708634.F7

Libby, 2009, New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 32, 1620, 10.2337/dc08-2175

Zakikhani, 2010, Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells, Breast Cancer Res Treat, 10.1007/s10549-010-0763-9

Zakikhani, 2008, The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase, Cancer Prev Res (Phila Pa), 1, 369, 10.1158/1940-6207.CAPR-08-0081

Algire, 2008, Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth, Endocr Relat cancer, 15, 833, 10.1677/ERC-08-0038

Zakikhani, 2006, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells, Cancer Res, 66, 10269, 10.1158/0008-5472.CAN-06-1500

Rosenstock, 2009, Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study, Diabetologia, 52, 1778, 10.1007/s00125-009-1415-7

Shaw, 2004, Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology, Rev Endocr Metab Disord, 5, 199, 10.1023/B:REMD.0000032408.18015.b1

Home, 2009, Combined randomised controlled trial experience of malignancies in studies using insulin glargine, Diabetologia, 52, 2499, 10.1007/s00125-009-1530-5

Dejgaard, 2009, No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis, Diabetologia, 52, 2507, 10.1007/s00125-009-1568-4

Lambe, 1994, Transient increase in the risk of breast cancer after giving birth, N Engl J Med, 331, 5, 10.1056/NEJM199407073310102

Séradour, 2009, Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006, Bull Cancer, 96, E1

Sjöström, 2009, Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial, Lancet Oncol, 10, 653, 10.1016/S1470-2045(09)70159-7

Renehan, 2009, Bariatric surgery, weight reduction, and cancer prevention, Lancet Oncol, 10, 640, 10.1016/S1470-2045(09)70170-6